1European Institute of Oncology, Milan, Italy [email protected]
Dr. Fazio reports serving on the advisory board and being a paid speaker for AAA Pharmaceutical and Merck, serving on the advisory board for Novartis, Hutchmed, and Merck Sharp and Dohme, receiving research grants from AAA Pharmaceutical, Merck, and Ipsen, serving as local primary investigator of clinical trials for 4SC, Astellas Pharma, BeiGene, FibroGen, Incyte, and Ipsen, serving as an internal reviewer of neuroendocrine tumor guidelines for the Italian Association of Medical Oncology, serving as a member of the executive committee of the European Neuroendocrine Tumor Society, serving as a member of the neuroendocrine tumor faculty of the European Society for Medical Oncology, and serving as a member of the steering committee of the Scholarly Publishing and Academic Resources Coalition (SPARC) Europe. No other potential conflict of interest relevant to this letter was reported.
